MECP2 and myelodysplastic syndrome: In a humanized mouse model of MDS, intracerebroventricular antisense oligonucleotide (ASO) therapy was shown to decrease MECP2 expression in the brain and to reduce behavioral deficits as well as to restore/correct reduced IFN-γ mRNA levels in the blood [129].